Natco Pharma – Imminent Growth Cycle (?)

Summary of valuation of Pharma companies by I-sec report.
Natco continues to be the cheapest, with 20% PAT growth projected ( by management on concall).
Rerating may happen if revenue or PAT have upside surprise.